Press Release – March 4, 2014

Press Release – March 4, 2014

Dymaxium adds the Medical Letter to the growing scientific evidence and resources available in Version 2.0 of the AMCP eDossier System

Toronto, ON - Dymaxium Healthcare Innovations, Inc is pleased to announce that the AMCP eDossier System will now have access to the Medical Letter, as part of the growing evidence and resources available to US health care decision makers.  As Version 2.0 continues to be rolled out in 2014, the System now has over 150,000 evidence references from 20 leading scientific sources for the 1400 products in the System.  

The AMCP eDossier System powered by Dymaxium's Formulary Decisions® platform, in partnership with the Academy of Managed Care Pharmacy (AMCP), is a centralized, secured product evaluation resource that streamlines connectivity, communication and collaboration between formulary decision makers and pharmaceutical manufacturers.  The new Version was unveiled originally at the AMCP Nexus meeting in late October, to critical acclaim.  Building upon the strength of the AMCP eDossier System, launched in 2010, Version 2.0 has a new interface, new tools and functionality, and a multitude of scientific resources to aid formulary decision makers in payer and healthcare organizations.

The Medical Letter is one of the leading resources for unbiased, and reliable drug information for physicians and pharmacists.  It is now available for 2014, as part of the premium content offered to active users of the System.  This access to this renowned publication will further enhance the product evaluation processes and the usability of the system.  

"Having the Medical Letter as part of the System is of significant benefit to the users" said Allen Lising, Managing Director, Dymaxium.  "Version 2.0 has the added benefit of providing the latest evidence and research from leading scientific sources such as PubMed, FDA, Cochrane.  Adding such a credible, highly respected resource such as the Medical Letter will further enhance the System, and greatly assist decision makers in Payer organizations in making informed, evidence-based formulary, reimbursement decisions.  We will continue to add additional resources to ensure that decision makers can access all the research, tools and insights they need for their product evaluations".  

"Providing access to objective, peer-reviewed evaluations is the Medical Letter's mandate" says -Yosef Wissner-Levy Vice President and  Publisher of the Medical Letter. " And as payers evaluate products and look to the most reliable information sources, the Medical Letter is one of the leading trusted resources designed to ensure that our drug information represents an unbiased consensus of scientific experts without undue influence of any parties".

About Dymaxium Healthcare Innovations, Inc ( Dymaxium is a global provider of solutions and tools focused on maximizing the communication and application of clinical, economic, and humanistic outcomes research.  Through the design, development, and implementation of innovative solutions and custom tools, Dymaxium helps bridge the gap between quality research and healthcare decision maker needs.   Since 1996, Dymaxium has implemented over 800+ unique solutions to manufacturers from around the world.  In 2009, Dymaxium Healthcare Innovations, a subsidiary of Dymaxium's designed and developed its Formulary Decisions® platform to support formulary decision makers in their product evaluations, and fostering connectivity, communication and collaboration with other decision makers and manufacturers.  (

About The Medical Letter
The Medical Letter, Inc. is a nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of previously approved drugs in its newsletters: The Medical Letter on Drugs and Therapeutics and Treatment Guidelines from The Medical Letter.  These publications are intended specifically to meet the needs of busy healthcare professionals who want unbiased, reliable and timely drug information. The editorial process used for both publications relies on a consensus of experts to evaluate the drug facts in order to help prescribers choose the most effective drug treatment. The Medical Letter and Treatment Guidelines are crucial resources for objective drug information and are completely independent of pharmaceutical industry influence. For more information call (800) 211-2769 or go to

Joanne Valentino
Director Marketing & Communications
The Medical Letter Inc.
145 Huguenot St., Suite 312
New Rochelle, NY 10801
Phone: 914.235.0500 Ext. 345

Allen Lising Managing Director Dymaxium Healthcare Innovations, Ltd.